Key result
Cilostazol prolongs pacemaker-free survival for 650 days in a feline high-grade AV block case.
Why the study?
Does cilostazol improve clinical signs and survival in a cat with high-grade atrioventricular block?
Case Report (n=1)
Does cilostazol improve clinical signs and survival in a cat with high-grade atrioventricular block?
Cilostazol may offer a long-term medical management option for high-grade AV block in cats when pacemaker implantation is not feasible.
May warrant cilostazol trial in cats with high-grade AV block when pacing unavailable; leaves open confirmation in prospective studies.
CASE SUMMARY: A 12-year-old neutered female domestic shorthair cat was admitted for syncope. Clinical signs and electrocardiography revealed high-grade atrioventricular (AV) block. Treatment with cilostazol ameliorated the clinical signs and arrhythmia. However, the high-grade AV block recurred on several occasions. After 640 days, the cat presented again with clinical deterioration owing to reoccurrence of the arrhythmia and it died 11 days later. Histopathological examination revealed a loss of conduction cells within the His bundle. RELEVANCE AND NOVEL INFORMATION: To our knowledge, this is the first report of high-grade AV block treated with cilostazol in a cat. Treatment with cilostazol prolonged survival for 650 days without pacemaker implantation. Histological findings suggested that the AV block was related to fibrosis of the impulse conduction system.
No takes yet. Share an insight, caveat, or question.
Iwasa et al. (2019) conducted a case report in High-grade atrioventricular (AV) block (n=1). Cilostazol was evaluated on Survival without pacemaker implantation. Treatment with cilostazol in a 12-year-old cat with high-grade AV block prolonged survival for 650 days without pacemaker implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: